Nasdaq1 个月
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory ...
About the Odronextamab Clinical Development ProgramOdronextamab is a CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell ...
pharmaphorum3 天
FDA turns down Regeneron bispecific blood cancer antibody
The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...
pharmaphorum2 天
After FDA no, Regeneron gets yes from EU on odronextamab
Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US. Ordspono (odronextamab) has been ...
Finanznachrichten1 个月
Regeneron Pharmaceuticals, Inc.: Odronextamab BLA Accepted for FDA Review for the Treatment ...
About the Odronextamab Clinical Development Program Odronextamab is a CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell ...
Regeneron gets FDA Review acceptance for odronextamab's resubmitted BLA
Regeneron Pharmaceuticals (NASDAQ:REGN) said on Wednesday that the U.S. FDA has accepted its resubmitted Biologics License ...
Yahoo Finance1 个月
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory ...
About the Odronextamab Clinical Development Program Odronextamab is a CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell ...
Nasdaq1 个月
FDA Accepts BLA Resubmission For Regeneron's Odronextamab In Follicular Lymphoma
(REGN) Wednesday said that the U.S. Food and Drug Administration (FDA) has accepted resubmission of the Biologics License Application (BLA) for odronextamab to treat relapsed/refractory (R/R ...